New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
18:25 EDTALNYAlnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1
Alnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1 for the treatment of acute intermittent porphyria, an ultra-rare genetic disease caused by loss of function mutations in an enzyme in the heme biosynthesis pathway that result in acute and/or recurrent life-threatening attacks with severe abdominal pain, peripheral and autonomic neuropathy, and neuropsychiatric manifestations. In aggregate, we believe that execution on our ‘Alnylam 5x15’ programs and our ambitious goals for 2013 and beyond will enable continued advancement of RNAi therapeutics as innovative medicines for patients, resulting in value creation for our shareholders.”
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:06 EDTALNYAlnylam initiates EXPLORE trial
Alnylam Pharmaceuticals and collaborators from the American Porphyria Consortium and The European Porphyria Network have initiated the EXPLORE trial, a prospective observational study of patients with hepatic porphyrias, including Acute Intermittent Porphyria, Variegate Porphyria, and Hereditary Coproporphyria, suffering from recurrent attacks. With this study, Alnylam and clinical investigators aim to learn more about the clinical course, management, and disease burden of patients with hepatic porphyrias that suffer from recurrent attacks. Alnylam is currently advancing ALN-AS1, a subcutaneously administered investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of hepatic porphyrias, and expects to file an IND or IND equivalent in late 2014 or early 2015. EXPLORE is a prospective, multi-center observational study designed to enroll up to 100 patients with hepatic porphyrias and a history of recurrent attacks. The study’s primary objective is to characterize the natural history, clinical management, and disease burden of patients with hepatic porphyrias. The study’s secondary objectives are to further characterize a number of disease features of hepatic porphyrias, including: (i) signs and symptoms of porphyria during acute attacks; (ii) levels of plasma and urinary aminolevulinic acid and porphobilinogen, the toxic intermediates of the heme biosynthesis pathway that cause the symptoms and disease pathology of the acute hepatic porphyrias; (iii) expression levels of aminolevulinic acid synthase-1 during acute attacks; and (iv) medical and family history of hepatic porphyria patients. Data obtained from EXPLORE are expected to further the understanding of hepatic porphyrias and to assist the design of clinical trials with ALN-AS1.
07:28 EDTALNYLeerink to hold a roundtable
Subscribe for More Information
September 26, 2014
07:32 EDTALNYBioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
September 24, 2014
08:08 EDTALNYAlnylam initiates DISCOVERY trial
Subscribe for More Information
September 18, 2014
07:49 EDTALNYAlnylam resumed with an Outperform at Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use